Adenovirus-mediated over-expression of Nrf2 within mesenchymal stem cells (MSCs) protected rats against acute kidney injury

Advanced Pharmaceutical Bulletin

Volumn 5, Issue 2, 2015, Pages 201-208

  Mohammadzadeh Vardin, Mohammad ^a   Roudkenar, Mehryar Habibi ^b   Jahanian Najafabadi, Ali ^c  

^a ARDABIL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute Kidney Injury; Cisplatin; Mesenchymal Stromal Cells (MSCs); NF E2 Related Factor 2(Nrf2)

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; TRANSCRIPTION FACTOR NRF2;

ACUTE KIDNEY FAILURE; ADENOVIRIDAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE CONSTRUCT; GENE OVEREXPRESSION; GENETIC ENGINEERING; IMPLANTATION; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NRF2 GENE; PLASMID; RAT; RENAL PROTECTION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 84930386699     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.15171/apb.2015.028     Document Type: Article

References (67)

1. Racusen LC. The morphologic basis of acute renal failure. In: Molitoris BA, Finn WF, editors. Acute renal failure: a companion to Brenner and Rector's the kidney, 1st ed. Philadelphia: WB Saunders; 2001:1-12.
2. Liu KD, Brakeman PR. Renal repair and recovery. Crit Care Med 2008;36(4 Suppl):S187-92. doi: 10.1097/ccm.0b013e318168ca4a.
3. Bussolati B, Hauser PV, Carvalhosa R, Camussi G. Contribution of stem cells to kidney repair. Curr Stem Cell Res Ther 2009;4(1):2-8. doi: 10.2174/157488809787169129.
4. De Fatima Fernandes Vattimo M, Da Silva NO. Uncaria tomentosa and acute ischemic kidney injury in rats. Rev Esc Enferm USP 2011;45(1):194-8.
5. Gnecchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol 2009;482:281-94. doi: 10.1007/978-1-59745-060-7_18.
6. Humphreys BD, Bonventre JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med 2008;59(1):311-25. doi: 10.1146/annurev.med.59.061506.154239.
7. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010;28(3):585-96. doi: 10.1002/stem.269.
8. Wang N, Li Q, Zhang L, Lin H, Hu J, Li D, et al. Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6. PLoS One 2012;7(8):e43768. doi: 10.1371/journal.pone.0043768.
9. Efrati S, Berman S, Hamad RA, Siman-Tov Y, Ilgiyaev E, Maslyakov I, et al. Effect of captopril treatment on recuperation from ischemia/reperfusion-induced acute renal injury. Nephrol Dial Transplant 2012;27(1):136-45. doi: 10.1093/ndt/gfr256.
10. Yo Y, Morishita R, Nakamura S, Tomita N, Yamamoto K, Moriguchi A, et al. Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apoptotic action of HGF on epithelial cells. Kidney Int 1998;54(4):1128-38. doi: 10.1046/j.1523-1755.1998.00092.x.
11. Mahmoudi M, Willgoss D, Cuttle L, Yang T, Pat B, Winterford C, et al. In vivo and in vitro models demonstrate a role for caveolin-1 in the pathogenesis of ischaemic acute renal failure. J Pathol 2003;200(3):396-405. doi: 10.1002/path.1368.
12. Yamada M, Pat B, Gobe G, Wojcikowski K. Angelica sinensis has inherent endothelial cell toxicity at high concentrations but can also protect the vascular endothelium from oxidative stress-induced injury at moderate concentrations. Altern Med Stud 2011;1(1):e8. doi: 10.4081/ams.2011.e8.
13. Zhu H, Zhang L, Itoh K, Yamamoto M, Ross D, Trush MA, et al. Nrf2 controls bone marrow stromal cell susceptibility to oxidative and electrophilic stress. Free Radic Biol Med 2006;41(1):132-43. doi: 10.1016/j.freeradbiomed.2006.03.020.
14. Surh YJ, Kundu JK, Na HK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 2008;74(13):1526-39. doi: 10.1055/s-0028-1088302.
15. Lee JM, Johnson JA. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 2004;37(2):139-43. doi: 10.5483/BMBRep.2004.37.2.139.
16. Osburn WO, Wakabayashi N, Misra V, Nilles T, Biswal S, Trush MA, et al. Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion. Arch Biochem Biophys 2006;454(1):7-15. doi: 10.1016/j.abb.2006.08.005.
17. Levonen AL, Inkala M, Heikura T, Jauhiainen S, Jyrkkanen HK, Kansanen E, et al. Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo. Arterioscler Thromb Vasc Biol 2007;27(4):741-7. doi: 10.1161/01.atv.0000258868.80079.4d.
18. Jin W, Wang H, Ji Y, Zhu L, Yan W, Qiao L, et al. Genetic ablation of Nrf2 enhances susceptibility to acute lung injury after traumatic brain injury in mice. Exp Biol Med (Maywood) 2009;234(2):181-9. doi: 10.3181/0807-rm-232.
19. Mohammadzadeh M, Halabian R, Gharehbaghian A, Amirizadeh N, Jahanian-Najafabadi A, Roushandeh AM, et al. Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity. Cell Stress Chaperones 2012;17(5):553-65. doi: 10.1007/s12192-012-0331-9.
20. Afonyushkin T, Oskolkova OV, Binder BR, Bochkov VN. Involvement of CK2 in activation of electrophilic genes in endothelial cells by oxidized phospholipids. J Lipid Res 2011;52(1):98-103. doi: 10.1194/jlr.m009480.
21. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, et al. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res 2011;71(6):2260-75. doi: 10.1158/0008-5472.can-10-3007.
22. Roudkenar MH, Ghasemipour Z, Halabian R, Roushandeh AM, Yaghmai P, Gharehbaghian A, et al. Lipocalin 2 acts as a cytoprotective factor against cisplatin toxicity, an in vitro study. DARU 2008;16(2):106-11.
23. Imberti B, Morigi M, Tomasoni S, Rota C, Corna D, Longaretti L, et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol 2007;18(11):2921-8. doi: 10.1681/asn.2006121318.
24. Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004;15(7):1794-804. doi: 10.1097/01.asn.0000128974.07460.34.
25. Morigi M, Benigni A, Remuzzi G, Imberti B. The regenerative potential of stem cells in acute renal failure. Cell Transplant 2006;15 Suppl 1:S111-7. doi: 10.3727/000000006783982449.
26. Proceedings from the Cleveland Clinic Workshop on Innovation in Treatment of Uremia. Seminars in dialysis 2009;22(6):597-708.
27. Togel FE, Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. Nature reviews Nephrology 2010;6(3):179-83. doi: 10.1038/nrneph.2009.229.
28. Zarjou A, Kim J, Traylor AM, Sanders PW, Balla J, Agarwal A, et al. Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1. Am J Physiol Renal Physiol 2011;300(1):F254-62. doi: 10.1152/ajprenal.00594.2010.
29. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005;289(1):F31-42. doi: 10.1152/ajprenal.00007.2005.
30. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004;14(6):1035-41. doi: 10.3892/ijmm.14.6.1035.
31. Poulsom R, Forbes SJ, Hodivala-Dilke K, Ryan E, Wyles S, Navaratnarasah S, et al. Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 2001;195(2):229-35. doi: 10.1002/path.976.
32. Grenz A, Hong JH, Badulak A, Ridyard D, Luebbert T, Kim JH, et al. Use of a hanging-weight system for isolated renal artery occlusion. J Vis Exp 2011;19(53). doi: 10.3791/2549.
33. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007;99(5):732-8. doi: 10.1016/j.amjcard.2006.09.125.
34. Zhu W, Chen J, Cong X, Hu S, Chen X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 2006;24(2):416-25. doi: 10.1634/stemcells.2005-0121.
35. Park MK, Kim WS, Lee YS, Kang YJ, Chong WS, Kim HJ, et al. Glucose oxidase/glucose induces apoptosis in C6 glial cells via mitochondria-dependent pathway. J Appl Pharmacol 2005;13(4):207.
36. Rodrigues M, Griffith LG, Wells A. Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res Ther 2010;1(4):32. doi: 10.1186/scrt32.
37. Rodrigues M, Blair H, Stockdale L, Griffith L, Wells A. Surface tethered epidermal growth factor protects proliferating and differentiating multipotential stromal cells from FasL-induced apoptosis. Stem Cells 2013;31(1):104-16. doi: 10.1002/stem.1215.
38. Reisman SA, Yeager RL, Yamamoto M, Klaassen CD. Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. Toxicol Sci 2009;108(1):35-47. doi: 10.1093/toxsci/kfn267.
39. Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, et al. Nrf2, a multi-organ protector? FASEB J 2005;19(9):1061-6. doi: 10.1096/fj.04-2591hyp.
40. Tufekci KU, Civi Bayin E, Genc S, Genc K. The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease. Parkinsons Dis 2011;2011:314082. doi: 10.4061/2011/314082.
41. Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, et al. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002;26(2):175-82. doi: 10.1165/ajrcmb.26.2.4501.
42. Chen XL, Dodd G, Thomas S, Zhang X, Wasserman MA, Rovin BH, et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 2006;290(5):H1862-70. doi: 10.1152/ajpheart.00651.2005.
43. Li J, Ichikawa T, Villacorta L, Janicki JS, Brower GL, Yamamoto M, et al. Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol 2009;29(11):1843-50. doi: 10.1161/atvbaha.109.189480.
44. Kweider N, Fragoulis A, Rosen C, Pecks U, Rath W, Pufe T, et al. Interplay between Vascular Endothelial Growth Factor (VEGF) and Nuclear Factor Erythroid 2-related Factor-2 (Nrf2): Implications for preeclampsia. J Biol Chem 2011;286(50):42863-72. doi: 10.1074/jbc.m111.286880.
45. Maher J, Yamamoto M. The rise of antioxidant signaling-the evolution and hormetic actions of Nrf2. Toxicol Appl Pharmacol 2010;244(1):4-15. doi: 10.1016/j.taap.2010.01.011.
46. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8(4):R204-12. doi: 10.1186/cc2872.
47. Van Biesen W, Vanholder R, Lameire N. Defining acute renal failure: RIFLE and beyond. Clin J Am Soc Nephrol 2006;1(6):1314-9. doi: 10.2215/cjn.02070606.
48. Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 2009;20(3):672-9. doi: 10.1681/asn.2008070669.
49. Ricci Z, Cruz DN, Ronco C. Classification and staging of acute kidney injury: beyond the RIFLE and AKIN criteria. Nat Rev Nephrol 2011;7(4):201-8. doi: 10.1038/nrneph.2011.14.
50. Wang YH, Li F, Schwartz JH, Flint PJ, Borkan SC. c-Src and HSP72 interact in ATP-depleted renal epithelial cells. Am J Physiol Cell Physiol 2001;281(5):C1667-75.
51. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006;17(6):1503-20. doi: 10.1681/asn.2006010017.
52. Havasi A, Wang Z, Gall JM, Spaderna M, Suri V, Canlas E, et al. Hsp27 inhibits sublethal, Src-mediated renal epithelial cell injury. Am J Physiol Renal Physiol 2009;297(3):F760-8. doi: 10.1152/ajprenal.00052.2009.
53. Kathleen D, Liu GMC. Acute renal failure. In: Jamison RL, Wilkinson R, editors. Nephrology. London: New York: Chapman & Hall; 2010.
54. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol 2011;7(4):189-200. doi: 10.1038/nrneph.2011.16.
55. Bajwa SJ, Sharma V. Peri-operative renal protection: The strategies revisited. Indian J Urol 2012;28(3):248-55. doi: 10.4103/0970-1591.102691.
56. Kwak MK, Kensler TW. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 2010;244(1):66-76. doi: 10.1016/j.taap.2009.08.028.
57. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006;21(5):689-700. doi: 10.1016/j.molcel.2006.01.013.
58. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006;3(10):e420. doi: 10.1371/journal.pmed.0030420.
59. Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y, Park YM. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res 2007;67(2):546-54. doi: 10.1158/0008-5472.can-06-2401.
60. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236(2):313-22. doi: 10.1006/bbrc.1997.6943.
61. Rushmore TH, Kong AN. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 2002;3(5):481-90. doi: 10.2174/1389200023337171.
62. Nguyen T, Yang CS, Pickett CB. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 2004;37(4):433-41. doi: 10.1016/j.freeradbiomed.2004.04.033.
63. Kim YJ, Baek SH, Bogner PN, Ip C, Rustum YM, Fakih MG, et al. Targeting the Nrf2-Prx1 pathway with selenium to enhance the efficacy and selectivity of cancer therapy. J Cancer Mol 2007;3(2):37-43.
64. Bi B, Schmitt R, Israilova M, Nishio H, Cantley LG. Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 2007;18(9):2486-96. doi: 10.1681/asn.2007020140.
65. Kucic T, Copland IB, Cuerquis J, Coutu DL, Chalifour LE, Gagnon RF, et al. Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failure-induced anemia. Am J Physiol Renal Physiol 2008;295(2):F488-96. doi: 10.1152/ajprenal.00044.2008.
66. Morigi M, Introna M, Imberti B, Corna D, Abbate M, Rota C, et al. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008;26(8):2075-82. doi: 10.1634/stemcells.2007-0795.
67. Yuan L, Wu MJ, Sun HY, Xiong J, Zhang Y, Liu CY, et al. VEGF-modified human embryonic mesenchymal stem cell implantation enhances protection against cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 2011;300(1):F207-18. doi: 10.1152/ajprenal.00073.2010.